Low-dose radiation plus rapamycin promotes long-term bone marrow chimerism

Transplantation

Volumn 80, Issue 11, 2005, Pages 1541-1545

  Powell, Jonathan D ^a   Fitzhugh, Courtney ^b   Kang, Elizabeth M ^b   Hsieh, Mathew ^b   Schwartz, Ronald H ^c   Tisdale, John F ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Chimerism; Hematopoietic; Rapamycin

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; BONE MARROW TRANSPLANTATION; CHIMERA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; FEMALE; GRAFT REJECTION; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE;

ANIMALS; BONE MARROW TRANSPLANTATION; FEMALE; FLOW CYTOMETRY; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MODELS, ANIMAL; SIROLIMUS; TRANSPLANTATION CHIMERA; TRANSPLANTATION CONDITIONING;

EID: 29344456390     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000185299.72295.90     Document Type: Article

References (23)

1. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions tor treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76 (12): 2462.
2. Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86 (5): 2041.
3. Barrett J, Childs R. New directions in allogeneic stem cell transplantation. Semin Hematol 2002; 39 (1): 1.
4. Bierer BE, Hollander G, Fruman D, Burakoff SJ. Cyclosporin A and FK506: molecular mechanisms of immunosuppression and probes for transplantation biology. Curr Opin Immunol 1993; 5(5): 763.
5. Goodnow CC. Pathways for self-tolerance and the treatment of autoimmune diseases. Lancet 2001; 357 (9274): 2115.
6. Abraham RT. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr Opin Immunol 1998; 10 (3): 330.
7. Powell JD, Lerner CG, Schwartz RH. Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation. J Immunol 1999; 162 (5): 2775.
8. Swanson SJ, Hale DA, Mannon RB, et al. Kidney transplantation with rabbit antithymocyte globulin induction and sirolimus monotherapy. Lancet 2002; 360 (9346): 1662.
9. Hirshberg B, Preston EH, Xu H, et al. Rabbit antithymocyte globulin induction and sirolimus monotherapy supports prolonged islet allograft function in a nonhuman primate islet transplantation model. Transplantation 2003; 76 (1): 55.
10. Volosov A, Napoli KL, Soldin SJ. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry. Clin Biochem 2001; 34 (4): 285.
11. Hale DA, Gottschalk R, Maki T, Monaco AP. Determination of an improved sirolimus (rapamycin)-based regimen for induction of allograft tolerance in mice treated with antilymphocyte serum and donor-specific bone marrow. Transplantation 1998; 65 (4): 473.
12. Hale DA, Gottschalk R, Umemura A, et al. Establishment of stable multilineage hematopoietic chimerism and donor-specific tolerance without irradiation. Transplantation 2000; 69 (7): 1242.
13. Umemura A, Monaco AP, Maki T. Donor MHC class II antigen is essential for induction of transplantation tolerance by bone marrow cells. J Immunol 2000; 164 (9): 4452.
14. Hale DA, Gottschalk R, Umemura A, et al. Immunologic mechanisms in tolerance produced in mice with nonradiation-based lymphoablation and donor-specific bone marrow. Transplantation 2002; 74 (4): 477.
15. Taylor PA, Lees CJ, Wilson JM, et al. Combined effects of calcineurin inhibitors or sirolimus with anti-CD40L mAb on alloengraftment under nonmyeloablative conditions. Blood 2002; 100 (9): 3400.
16. Johnson FL, Look AT, Gockerman J, et al. Bone-marrow transplantation in a patient with sickle-cell anemia. N Engl J Med 1984;311 :780.
17. Johnson FL, Mentzer WC, Kalinyak KA, et al. Bone marrow transplantation for sickle cell disease. The United States experience. Am J Pediatr Hematol Oncol 1994; 16 (1): 22.
18. Vermylen C, Fernandez Robles, E, Ninane J, Cornu G. Bone marrow transplantation in five children with sickle cell anaemia. Lancet 1988; 1 (8600): 1427.
19. Vermylen C, Cornu G, Ferster A, et al. Bone marrow transplantation in sickle cell disease: the Belgian experience. Bone Marrow Transplant 1993;12 :116.
20. Vermylen C, Cornu G. Bone marrow transplantation for sickle cell disease. The European experience. Am J Pediatr Hematol Oncol 1994; 16(1): 18.
21. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant 1998; 22 (1): 1.
22. Walters MC, Patience M, Leisenring W, et al. Collaborative multicenter investigation of marrow transplantation for sickle cell disease: current results and future directions. Biol Blood Marrow Transplant 1997; 3 (6): 310.
23. Iannone R, Casella JF, Fuchs EJ, et al. Results of minimally toxic non-myeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003; 9 (8): 519.